Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the ...
Medscape

TYK2 Inhibitor Promising for Moderate-to-Severe Psoriasis in Phase 3 Studies

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
The American Journal of Managed Care

Dual-Target Strategy Shows Promise in Overcoming Drug Resistance in MCL

“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
Pulmonology Advisor

Molecular Glue Degrader TRI-611 Receives FDA Fast Track for ALK+ NSCLC

The Food and Drug Administration (FDA) has granted Fast Track designation to TRI-611 for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
News Medical

Insights into kinase inhibitors' therapeutic potential in neurodegenerative diseases

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...